Foetal Polymix Stem Cell Composition for Enhanced Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapy protocols face limitations due to the use of adult mesenchymal stem cells, which have limited multi-potency, slower proliferation rates, and require invasive sourcing, leading to inconsistent therapeutic results. Additionally, existing methods do not utilize hypoxic preconditioning to enhance stem cell viability and potency.
Innovation Solution
A method involving the isolation, enrichment, and co-culture of mesenchymal stem cells from foetal sources such as the placenta, amniotic membrane, chorion, and umbilical cord under hypoxic or normoxic conditions, creating a polymix composition that includes chorionic villi stem cells, amniotic progenitor cells, avascular amnion stem cells, vascular amnion stem cells, and umbilical cord stem cells, which are then administered via various routes to treat a range of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If adult mesenchymal stem cells are used for therapy, then the therapy can be administered, but the multi-potency is limited and proliferation rate is slow
Solution Approach 1:
The patent changes the source parameter from adult to foetal, and the culture condition parameter from normoxic to hypoxic (1-5% oxygen). This combination parameter change transforms the stem cell properties to achieve both high multi-potency (differentiating into all three embryonic layers) and high proliferation rate (faster than adult MSCs), resolving the technical contradiction between these two features.
2Quantity of substance
If bone marrow mesenchymal stem cells are isolated, then stem cells can be obtained, but invasive procedure is required and cell numbers are limited
Solution Approach 1:
The patent extracts stem cells from extra-embryonic perinatal sources (placenta, amniotic membrane, chorion, umbilical cord) that are readily available after childbirth, eliminating the need for invasive bone marrow procedures. This extraction from alternative sources provides abundant cell numbers without surgical intervention, resolving the contradiction between cell quantity and ease of sourcing.
3Quantity of substance
If mesenchymal stem cells are expanded in-vitro, then cell numbers increase, but stemness properties are lost and chromosomal changes occur
Solution Approach 1:
The patent changes the oxygen concentration parameter from normoxic (20%) to hypoxic (1-5%) conditions during in-vitro expansion. This parameter change maintains stemness properties and prevents chromosomal abnormalities while still achieving the required cell numbers for therapy, resolving the contradiction between quantity and reliability.
4Reliability
If single-type stem cell therapy is administered, then the treatment can be delivered, but therapeutic results are inconsistent
Solution Approach 1:
The patent merges multiple types of foetal mesenchymal stem cells (from placenta, amniotic membrane, chorion, and umbilical cord) into a single polymix composition. This combination provides consistent and enhanced therapeutic results by leveraging the complementary properties of different cell types, resolving the contradiction between reliability of outcome and complexity of composition.
Data Source
AI summary
A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.